Full Press Release Details
SAN DIEGO , Aug. 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor conferences.
Dr. Helen Torley , president and chief executive officer of Halozyme, will participate in Citigroup's 13 th Annual Biotech Conference in Boston on Wednesday, September 5, 2018 . Dr. Torley will represent Halozyme on a panel titled "Targeted Therapies Oncology – Aiming for the Bull's Eye" at the conference.
On Thursday, September 6, 2018 , Dr. Torley will present an overview of the company at the 2018 Wells Fargo Securities Healthcare Conference in Boston at 1:20 p.m. ET / 10:20 a.m. PT . A live audio webcast of the presentation will be available in the "Investors" section of Halozyme's website at www.halozyme.com with an archived replay available for 90 days following the event.
About Halozyme Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for the treatment of several cancers and has the potential to be used in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb and Alexion for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego . For more information visit www.halozyme.com .
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 [email protected]
Laurie Stelzer 858-704-8222 [email protected]
SOURCE Halozyme Therapeutics, Inc.